David Veino – President and CEO
David was named President and CEO of Neuros in 2023, after serving as Chief Operating Officer since 2018.
Prior to Neuros, David worked for Cardiovascular Systems, Inc. (CSII), where he held a variety of senior executive positions and scaled the commercial organization from $50M in peripheral sales to over $250M in combined coronary and peripheral sales. During his tenure, David led the successful development of amputation prevention programs designed to drive awareness and access to care for underserved communities in the United States.
Prior to CSI, David served as General Manager for Stryker (SYK), where he led the creation of the Interventional Spine Division. David has also held key commercial leadership positions with Globus Medical (GMED) and other venture capital medical device companies.
David serves as a private equity advisor with Sectoral Asset Management. He earned a BS in Physiology from Chico State University and completed the Advanced Management Program at Harvard Business School.
William R. Patterson, PhD – Chief Technical Officer
Bill joined Neuros as CTO in 2021.
Prior to Neuros, Bill was the CTO at MicroVention, Inc., a Terumo Group Company, where he led the development of a number of neurovascular devices, and played a critical role in their CE Mark approvals, 510k clearances, and PMA approvals. In addition, Bill moderated a 2018 Neurology Devices PMA Advisory Committee meeting.
Bill earned his BS from University of California – Davis and his PhD in Biophysics from University of California – Irvine. He completed his scientific training as a post-doctoral fellow at the prestigious UCLA DOE Institute. He is an author or co-author on multiple peer-reviewed publications in diverse academic and medical fields; and is the inventor/co-inventor on over 40 US patents spanning cardiovascular devices, neurovascular devices, and, recently, machine learning and artificial intelligence.
Zi-Ping Fang, PhD – Chief Scientific Officer
Dr. Fang joined Neuros as employee number two, and currently serves as CSO.
During his tenure at Neuros, Dr. Fang led the technical and clinical development of the Altius system, including the design of the current QUEST pivotal study.
Across the past 30 years, Dr. Fang has guided the development of several neuromodulation technologies through pre-clinical, clinical research, and FDA approval. He has held executive R&D positions in technology-based startups including NeuroControl as VP R&D, and Nevro as Chief Scientist.
Dr. Fang received his PhD in Biomedical Engineering with a focus on neurostimulation technology from the pioneering laboratory of Prof. Thomas Mortimer at Case Western Reserve University.
Todd Rossman – Chief Financial Officer
Todd joined Neuros as consultant CFO in 2017.
Prior to Neuros, Todd held financial leadership positions in publicly-held companies, including Reliance Electric Company and Renaissance Hotel Group NV (Marriott International), and private-equity backed organizations, including Target Marketing Solutions and Interactive Information Services. Todd began his career in the Financial Statement Audit Practice at Price Waterhouse.
During his 35-year career, Todd has developed diverse financial transaction expertise, with experience in initial public offerings, business acquisitions and divestitures, including the sale of Renaissance to Marriott, and numerous financing transactions including bank debt, public debt, private debt and equity.
Todd currently serves as an Adjunct Instructor – Accounting at Kent State University. He received a BS from Miami University and his MBA from John Carroll University.
Nick Hargus, PhD – Vice President of Clinical and Medical Affairs
Nick joined Neuros in 2022.
Prior to Neuros, Nick was at Cardiovascular Systems, Inc. (CSII), where he last served as the Director of Medical Affairs, responsible for scientific communication and patient safety. During his 8-year tenure, Nick was responsible for the creation of a Medical Science Liaison program and provided medical affairs expertise to support the acquisition, approval, and launch of new products.
Prior to industry, Nick had a 10+ year career in academic science with appointments at the National Institutes of Health, University of Virginia, and University of Minnesota.
Nick earned his PhD in Neuroscience from the University of Virginia, where he studied sodium channel function and gating alterations in epilepsy and chronic pain. His work resulted in numerous peer-reviewed publications funded through multiple individual NIH-supported grants. He received his BS in Neuroscience from Lafayette College.
Melanie Parravi – Sr. Vice President of Quality & Regulatory Affairs
Melanie joined Neuros in 2018.
Prior to Neuros, she served as Vice President of Quality Assurance & Regulatory Compliance at Sequent Medical, Inc., acquired by Terumo Corporation in 2016 for up to $380M. During her tenure, Melanie was instrumental in the development of the WEB Aneurysm Embolization System and in the procurement of both US PMA and international regulatory approvals.
Melanie is a subject-matter expert in medical device quality management systems and regulatory affairs. Throughout her 30-year career, she has driven outstanding results in audits (ISO, FDA/QSR) and approvals (CE, 510k, and PMA) in high-growth, new technology companies.
Melanie earned a BS from University of California-Irvine.
Amy Smith – Vice President of Market Access and Global Marketing
Amy joined Neuros in 2018.
Prior to joining Neuros, Amy held a variety of marketing and sales leadership positions at Entellus Medical. During her tenure, she led numerous market development initiatives in the office-based ENT procedure space and helped evolve the Entellus organization from a pre-commercial start-up, through IPO, to subsequent acquisition by Stryker (SYK) for $662 million in 2018.
Prior to Entellus, Amy served in several marketing leadership roles at Boston Scientific in the Peripheral and Coronary Divisions. Prior to Boston Scientific, she held R&D and engineering management roles at SurModics and 3M.
Amy received a BS in Biochemical Engineering from University of Missouri.